SCHEMBL23578229

SCHEMBL23578229

C=C(Cc1nc(C2(c3ccc(OC(F)(F)C(F)F)cc3)CC2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ MAPT P10636 3/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ TRPV1 Q8NER1 1/20 0.32
▸ RBP1 P09455 2/20 0.31
▸ PKM P14618 1/20 0.31
▸ XBP1 P17861 1/20 0.31
▸ AKT1 P31749 1/20 0.31
▸ S1PR1 P21453 1/20 0.30
▸ ALOX5AP P20292 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29973341 0.93 S1PR1 (0.36) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23588198 0.90 CRHBP (0.35) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23578442 0.88 MEN1 (0.35) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23578242 0.88 KMT2A (0.36) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23588264 0.87 MEN1 (0.36) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23578490 0.87 KMT2A (0.37) MEN1KMT2AHTTLMNAMAPT
SCHEMBL25801899 0.86 KMT2A (0.35) MEN1KMT2AHTTLMNAMAPT
SCHEMBL25801800 0.86 KMT2A (0.46) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23578284 0.85 KMT2A (0.37) MEN1KMT2AHTTLMNAMAPT
SCHEMBL23588153 0.85 MEN1 (0.37) MEN1KMT2AHTTLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 — — US disclosed
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 — — EP disclosed
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 — — EP disclosed
EP-4081511-B1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2024-07-31 — — EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 — — WO disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 MEN1 4504/4885KMT2A 3125/4885HTT 4546/4885
US-12617762-B2 Carboxy derivatives with antiinflamatory properties CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 4588/4885KMT2A 4179/4885HTT 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback